Mr Hawkins spent the past seven years in founder and leadership roles developing and commercializing medical devices for incubators funded by Three Arch Partners, Frazier Healthcare, Prospect Ventures,
In addition to reducing the size of its management team, the company announced that Bernard Boudreau, Edgar Parker, Aditya Jah, Vasu Chanchlani and Michael Sefton have all resigned
Under the terms of the arrangement, GVK Biosciences and Excel will help sponsors conduct and manage Phase II-IV clinical trials, statistical analysis and medical writing. Any India trial
Sinovac Biotech, a China-based biopharmaceutical company, has reported a net income of $2.4m, or $0.06 per diluted share, for the fourth quarter of 2008, compared to $2m, or
According to Sun Pharma, these oxycodone tablets are therapeutically equivalent to Roxicodone tablets from Xanodyne Pharmaceuticals and are available in three strengths: 5mg, 15mg and 30mg. Oxycodone is
The companies have agreed to offer their services together to parties such as pharmaceutical companies, who may be seeking a patient-friendly intranasal Phylomer peptide developed against their target
The funding was triggered by the company’s achievement of a major milestone towards the development of its image guided cancer therapy device, the Renaissance system. The financing was
Through the collaboration, iZumi and Kyoto University’s Center for iPS Cell Research and Application (CiRA) will exchange part of their representative human induced pluripotent stem (iPS) cell lines
Thallion Pharmaceuticals, a biotechnology company developing pharmaceutical products in the areas of oncology and infectious disease, has reported a net loss of $3.24m or $0.10 per share in
ChemGenex Pharmaceuticals, an Australian biopharmaceutical development company, has completed a private placement to sophisticated and institutional investors in Australia and internationally to raise A$10m. ChemGenex placed 23.25 million
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.